Emerging therapies for glioblastoma: current state and future directions

L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022‏ - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

The emerging field of oncolytic virus-based cancer immunotherapy

R Ma, Z Li, EA Chiocca, MA Caligiuri, J Yu - Trends in cancer, 2023‏ - cell.com
Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with
cancers resistant to traditional therapies. Natural or genetically modified OVs are …

Immunotherapy: a promising approach for glioma treatment

F Yasinjan, Y **ng, H Geng, R Guo, L Yang… - Frontiers in …, 2023‏ - frontiersin.org
Gliomas are the most prevalent primary malignant brain tumors worldwide, with
glioblastoma (GBM) being the most common and aggressive type. Despite two decades of …

[HTML][HTML] Immunotherapy for glioma: current management and future application

S Xu, L Tang, X Li, F Fan, Z Liu - Cancer letters, 2020‏ - Elsevier
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …

Glioblastoma therapy: Past, present and future

E Obrador, P Moreno-Murciano… - International journal of …, 2024‏ - mdpi.com
Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …

Current state of immunotherapy for glioblastoma

M Lim, Y **a, C Bettegowda, M Weller - Nature reviews Clinical …, 2018‏ - nature.com
Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

Glioma diagnosis and therapy: current challenges and nanomaterial-based solutions

T Li, J Li, Z Chen, S Zhang, S Li, S Wageh… - Journal of controlled …, 2022‏ - Elsevier
Glioma is often referred to as one of the most dreadful central nervous system (CNS)-specific
tumors with rapidly-proliferating cancerous glial cells, accounting for nearly half of the brain …

Advances in immunotherapy for glioblastoma multiforme

AB Mahmoud, R A**a, S Aref, M Darwish… - Frontiers in …, 2022‏ - frontiersin.org
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor
of the central nervous system and has a very poor prognosis. The current standard of care …

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

J Fares, AU Ahmed, IV Ulasov, AM Sonabend… - The Lancet …, 2021‏ - thelancet.com
Background Malignant glioma is the most common and lethal primary brain tumour, with
dismal survival rates and no effective treatment. We examined the safety and activity of NSC …

Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies

A Hamad, GM Yusubalieva, VP Baklaushev… - Viruses, 2023‏ - mdpi.com
Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …